Results 71 to 80 of about 3,663 (172)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility

Качественная клиническая практика, 2018
Usage of PCSK9 inhibitors is a new approach of lipid lowering therapy allowing overcomes as well insusceptibility of standard statins’ therapy as their intolerance.
S. K. Zyryanov, I. N. Dyakov
doaj  

A register-based cohort study on the effectiveness and Safety of anti-PCSK9 treatment in persons with hyperlipidemia

Communications Medicine
Background Dyslipidemia is a known risk factor for cardiovascular disease. While statins are the primary treatment, some individuals require additional lipid-lowering therapies, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors ...
Michael Asger Andersen, Anne Helms Andreasen, Lia Evi Bang, Espen Jimenez-Solem, Tonny Studsgaard Petersen   +4 more
doaj   +1 more source

Adherence to PCSK9 Inhibitors in Clinical Practice: Systematic Review and Meta-Analysis of Observational Studies. [PDF]

JACC Adv
Blais JE, Zhong W, Li CYV, Kongkaew C, Chan AHY.   +4 more
europepmc   +1 more source

Focus on Baseline LDL-C and Patient Risk, Not Drug Type: A Perspective on Alirocumab vs Evolocumab. [PDF]

Rev Cardiovasc Med
Sabouret P, Giamundo DM, Mamas M.
europepmc   +1 more source

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]

Lipids Health Dis
Kafol J, Fras Z, Novakovic M, Sperling LS, Cevc M, Krevel B, Kafol L, Kelenc A, Kepic K, Vrbinc K, Svarc M, Groselj U, Jug B.   +12 more
europepmc   +1 more source

Alirocumab’s Price Reduction [PDF]

Circulation, 2018
Sanket S. Dhruva, Joseph S. Ross, Nihar R. Desai   +2 more
openaire   +1 more source

Small, dense LDL-C as a predictor of cardiovascular risk and benefit of alirocumab in patients with recent acute coronary syndrome receiving optimized statin treatment. [PDF]

Am J Prev Cardiol
Schwartz GG, Szarek M, Cobbaert CM, Ruhaak LR, Schwertfeger M, Bhatt DL, Bittner VA, Goodman SG, Harrington RA, Stevanovic I, Tavori H, Reijnders E, Romijn F, van Neer NJM, White HD, Jukema JW, Steg PG.   +16 more
europepmc   +1 more source

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering. [PDF]

Biomolecules
Espadas C, Soto-Catalán M, Romero-Cote M, Kavanagh M, Herrero-Del Real I, Ortega-Hernández A, Lumpuy-Castillo J, Gómez-Garre D, Egido J, Tuñón J, Gómez-Guerrero C, Lorenzo Ó.   +11 more
europepmc   +1 more source

Advancing Lipid Management: Saudi Heart Association Position Statement on PCSK9-targeted Therapies in the Primary and Secondary Prevention of Cardiovascular Disease. [PDF]

J Saudi Heart Assoc
AlHabeeb W, Alamri H, Elbadawi H, AlRuthia YS, Alharbi W, Alshammeri O, Tash A, Almoziny S, Kholaif N, Halawani H, AlMahdi F, Yar W, Alhabib KF.   +12 more
europepmc   +1 more source

Alirocumab <i>versus</i> Evolocumab on Cardiovascular Outcomes: A Systematic Review and Meta-analysis. [PDF]

Curr Cardiol Rev
Cleto AS, Schirlo JM, Machozeki J, Martins CM.   +3 more
europepmc   +1 more source